- Hologic has cut its full-year adjusted earnings per share (EPS) forecast.
- The new forecast for adjusted EPS is between $4.15 and $4.25, previously $4.25 to $4.35.
- The consensus estimate for adjusted EPS was $4.25.
- For the third quarter, Hologic expects adjusted EPS between $1.04 and $1.07, below the estimate of $1.09.
- In the second quarter, Hologic reported an adjusted EPS of $1.03, slightly above the consensus estimate of $1.02.
- Second-quarter revenue reached $1.01 billion, surpassing the estimate of $1 billion.
- The adjusted gross margin for the second quarter was 61.1%, higher than the expected 60.8%.
- The adjusted net margin was 23.2%, just below the estimate of 23.6%.
- Analyst recommendations include 7 buys, 14 holds, and 1 sell.
Hologic Inc on Smartkarma
Analyst coverage of Hologic Inc on Smartkarma by Baptista Research showcases a positive outlook on the company’s future. In the report titled “Hologic: The Future of 3D Mammography and Molecular Diagnostics—What’s Next?“, the analysis delves into Hologic, Inc.’s first-quarter fiscal 2025 results, highlighting operational efficiencies and revenue challenges. Despite facing some hurdles, the company achieved a 1% increase in revenue to $1.022 billion on a constant currency basis, with the impact of a stronger U.S. dollar mitigating revenue gains by approximately $9 million.
In another report by Baptista Research titled “Hologic Inc.: Expanding Diagnostic Assay Portfolio For A Competitive Edge! – Major Drivers,” the analyst emphasizes Hologic’s financial performance in the fourth quarter and fiscal year 2024. With total revenue reaching $987.9 million in Q4, representing a 4.2% year-on-year growth and a 5% organic revenue increase excluding COVID-related sales, the company shows overall strength. Additionally, non-GAAP earnings per share (EPS) surged by 13.5% to $1.01, indicating positive momentum in Hologic’s strategic expansion of its diagnostic assay portfolio for a competitive advantage.
A look at Hologic Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 1 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Hologic Inc shows a mixed outlook for the long term. While the company scores well in terms of resilience, indicating its ability to weather challenges and maintain stability, its dividend score is low, suggesting limited returns for shareholders in the form of dividends. Hologic Inc also scores moderately on value, growth, and momentum, reflecting a balanced performance across key factors.
Hologic Inc is a leading developer, manufacturer, and supplier of premium diagnostic products, medical imaging systems, and surgical products. With a strong focus on diagnostics, breast health, GYN surgical, and skeletal health, the company has established itself as a key player in the healthcare industry. Investors considering Hologic Inc for long-term investment should weigh the company’s resilience and growth potential against its lower dividend offering to make informed decisions.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
